Fabio Cataldi, Beverly, MA (US); Robert A. Clare, Wayne, PA (US); Gail M. Comer, Phoenixville, PA (US); Vivekananda Pradhan, Acton, MA (US); Alaa Ahmad, Arlington, MA (US); Mina Hassan-Zahraee, Cambridge, MA (US); Mera Krishnan Tilley, Medford, MA (US); Weidong Zhang, Acton, MA (US); Anindita Banerjee, Canton, MA (US); Karen Michelle Page, Merrimack, NH (US); Michael Steven Vincent, Newton, MA (US); and David J. Von Schack, Arlington, MA (US)
Assigned to Pfizer Inc., New York, NY (US)
Filed by PFIZER INC., New York, NY (US)
Filed on Nov. 30, 2020, as Appl. No. 17/107,228.
Application 17/107,228 is a division of application No. 15/542,110, granted, now 10,851,163, previously published as PCT/IB2016/050047, filed on Jan. 6, 2016.
Claims priority of provisional application 62/101,877, filed on Jan. 9, 2015.
Claims priority of provisional application 62/263,910, filed on Dec. 7, 2015.
Claims priority of provisional application 62/263,197, filed on Dec. 4, 2015.
Prior Publication US 2021/0324070 A1, Oct. 21, 2021
1. A method for treating ulcerative colitis in a patient comprising administering subcutaneously to the patient an initial dose of 22.5 mg of MAdCAM antagonist antibody comprising light chain SEQ ID NO: 1 and heavy chain SEQ ID NO: 2 once every 4 weeks for at least 12 weeks to achieve a clinical remission rate of at least 10% compared to baseline, wherein the clinical remission rate is determined using a MAYO score or a sccai score.